ArticlePakistan journal of medical sciences2026
Prevalence and profile of isoniazid mono-resistant tuberculosis in Pakistan: Insights from a decade of surveillance.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Isoniazid monoresistance poses a growing concern in tuberculosis (TB) management, as it can compromise treatment outcomes and increase risk of multidrug-resistant TB. With limited data on its prevalence and characteristics in Pakistan, identifying its prevalence and factors associated is imperative. This study, therefore aimed to identify prevalence and resistance profile of isoniazid mono-resistance isolates and association of isoniazid mono-resistance with demographic, TB category and patient status. Methodology: This retrospective study analyzed all Result: A total of 5,820 MTBC-positive cultures were evaluated. Among these, 140 (2.4%) were identified with isoniazid monoresistance. The prevalence fluctuated across the study period, with the highest rate observed in 2023 (3.5%). Most patients with isoniazid monoresistance had pulmonary TB (117; 83.6%) compared to extrapulmonary TB (23; 16.4%). The majority were newly enrolled cases (127; 90.7%). No statistically significant associations were found between isoniazid monoresistance and patient demographics or TB category. Conclusion: The prevalence of isoniazid monoresistance remained relatively low but showed a rising trend, peaking in 2023. Most cases occurred in newly enrolled pulmonary TB patients. Continuous surveillance and early detection are essential to guide treatment strategies and prevent the emergence of multidrug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.